Invion Ltd. · ASX:IVX

Invion — Shareholder Meeting (November 2021)

8 slides from Invion's shareholder meeting presentation, Nov 9, 2021

  1. Slide 1: Annual General Meeting 9 November 2021

    For personal use only ANNUAL GENERAL MEETING 9 NOVEMBER 2021 ©Copyright Invion Limited| A C N 094 730 417| A S X : I V X

  2. Slide 2: CEO Presentation

    For personal use only CEO PRESENTATION 2

  3. Slide 3: Key Achievements: Highlights Over the Past Year

    KEY ACHIEVEMENTS HIGHLIGHTS OVER THE PAST YEAR For personal use only Progressing towards the commercialisation of the next-generation PDT treatment for major diseases Promising Results: Latest PoC studies showed evidence of complete regression of TNBC tumours and ongoing protective immunity Improved

  4. Slide 4: Improved API – INV043

    IMPROVED API – INV043 KEY CHARACTERISTICS: INITIAL PROOF OF CONCEPT (PoC) For personal use only INV043 selected as lead Active Pharmaceutical Ingredient (API) for development of next-generation of PDT cancer treatments INV043 Activity Against B. Phototoxicity C.  Promising preliminary results that

  5. Slide 5: Pilot Proof of Concept Results

    PILOT PROOF OF CONCEPT RESULTS SECOND PoC STUDY ON IMMUNOCOMPETENT MICE For personal use only Early signs that INV043 can completely regress Triple Negative Breast Cancer (TNBC) tumours and trigger protective immunity  PoC pilot studies show complete regression of TNBC in vivo following INV043 trea

  6. Slide 6: New Market Opportunities: Expanded Territories and New Disease Areas

    NEW MARKET OPPORTUNITIES EXPANDED TERRITORIES AND NEW DISEASE AREAS For personal use only Invion signed Co-Development and Exclusive Distribution & Licence Agreements with RMW Cho Both will co-develop Photosoft™ technology for the treatment of atherosclerosis and infectious diseases (including viral

  7. Slide 7: New Market Opportunities: Expanded Territories and New Disease Areas

    NEW MARKET OPPORTUNITIES EXPANDED TERRITORIES AND NEW DISEASE AREAS For personal use only Invion’s exclusive territories gives it access to markets with >2.8 billion people Atherosclerosis Disease where plaque builds up inside arteries. Global treatment market is forecast to hit US$56.6 billion by 2

  8. Slide 8: The Way Forward: Pathway to Clinical Trials

    THE WAY FORWARD PATHWAY TO CLINICAL TRIALS For personal use only 1H 2022 2H 2022 Invion is building on early Clinical trial successes by identifying indication targets Conduct initial Cancer Additional PoC target cancer indications Pre-Clinical clinical trials with our partner institutions Preparati

Invion — Shareholder Meeting (November 2021) on 6ix